Machine learning platform for drug discovery and development.
Competing Products
Insitro
Insitro: Leveraging machine learning for data-driven drug discovery and development.
Insitro: Leveraging machine learning for data-driven drug discovery and development.
Founded in 2018, Insitro is a data-driven drug discovery and development company with a core mission to revolutionize the creation of medicines through the integration of machine learning and high-throughput biology. The company's vision is to transform the pharmaceutical industry by improving the efficiency and success rates of drug discovery processes. Insitro focuses on developing innovative therapeutics for various diseases by harnessing large-scale data and advanced computational models.
Notable affiliated individuals include Daphne Koller, a co-founder of Coursera and an influential figure in AI and computational biology, who serves as Insitro's CEO. The company has attracted significant investment from prominent venture capital firms such as Andreessen Horowitz and ARCH Venture Partners. Key achievements include strategic partnerships with major pharmaceutical companies like Gilead Sciences, which underscore Insitro's impact on the industry. By combining cutting-edge technology with biological insights, Insitro aims to accelerate the development of effective treatments, ultimately benefiting patients worldwide.
Companies similar to Insitro include Mithrl, 1910, Potato and Isomorphic Labs.
Insitro was founded in 2018.
Insitro's headquarters is located in South San Francisco, CA, US.
Insitro's most recent funding round was for $400M (USD) in March 2021.
As of Mar 15, 2021, Insitro has disclosed funding of $643M (USD). Undisclosed round amounts are excluded.
Insitro has 295 employees as of Feb 5, 2024.
readysetpotato.com